Trichotillomania is an impulse control disorder characterized by an overwhelming urge to pull out one's own hair, often resulting in patches of baldness. The hair on the scalp is most often affected. The eyelashes, eyebrows, and beard are also affected often. In some cases, affected individuals chew and/or swallow (ingest) the hair they have pulled out (trichophagy). The exact cause of trichotillomania is unknown. .
Individuals with trichotillomania repeatedly experience an overwhelming urge to pull out their hair. In most cases, they are extremely tense upon feeling such an impulse and do not experience relief until after they have pulled out the hair. Affected individuals may break off pieces of hair or pull out entire strands. Patches of baldness (alopecia) usually result on the scalp. The beard, eyelashes, and eyebrows are also commonly involved. In some cases, individuals may also pull hair from the armpits, trunk, and/or pubic areas. There may be a generalized tingling or itching (pruritis) in the involved areas, but affected individuals usually do not experience pain after hair plucking. In addition, affected individuals often have an uncontrollable urge to twist their hair. In some cases, affected individuals may chew or swallow (ingest) their hair, a condition known as trichophagy. In rare cases, ingestion of hair may lead the formation of a hairball in the stomach resulting in abdominal pain (trichobezoar).
Individuals with trichotillomania may deny that their hair-pulling behavior exists and may attempt to conceal the behavior by wearing wigs and false eyelashes and taking similar additional steps to hide hair loss.
In some cases, people with trichotillomania may also engage in other self-mutilating behaviors, such as abrading or wearing off of the skin (excoriation), scratching, gnawing, nail biting or banging their heads. Some individuals may also suck their thumbs. .
The exact cause of trichotillomania is not known. In some cases, it is believed that severely stressful situations play a role in causing this disorder. It is also felt that abuse of psychoactive drugs may help cause trichotillomania. Some scientists believe that trichotillomania is a subcategory of obsessive compulsive disorder (OCD), which may be caused by certain imbalances in brain chemicals (see OCD in related disorders section). When trichotillomania occurs in adulthood, it commonly accompanies a psychotic disorder. .
Trichotillomania usually occurs in childhood. However, the disorder has occurred in adults up to approximately 60 years of age. During childhood, the disorder may be more frequent in males; in adolescence and adulthood, females are affected more often. Trichotillomania has been known to affect individuals for a period of several months to more than 20 years. In many cases, symptoms may occur in cycles, with symptoms periodically lessening, then worsening, disappearing, and then recurring.
Because some cases of trichotillomania go unrecognized, the disorder is under-diagnosed, making it difficult to determine its true frequency in the general population. .
Symptoms of the following disorder can be similar to those of trichotillomania. Comparisons may be useful for a differential diagnosis:
Obsessive dompulsive disorder is characterized by recurrent obsessive and compulsive thoughts and actions. Obsessions are persistent ideas, thoughts, impulses or images that the affected individual knows are senseless. Attempts are made to ignore or suppress such thoughts or impulses, or to counteract them with some other thought or action. The individual recognizes that the obsessions are the product of his or her own mind, but they are difficult to resist. Many scientists believe that trichotillomania and obsessive compulsive disorder are caused by related brain chemical abnormalities because they are often responsive to the same drug treatments. (For more information on this disorder, choose "Obsessive Compulsive" as your search term in the Rare Disease Database.)
Monilethrix is a rare inherited disorder characterized by sparse, dry, and/or brittle hair that often breaks before reaching more than a few inches in length. The hair may lack luster, and there may be patchy areas of hair loss (alopecia). Another common symptom may be the appearance of elevated spots (papules) surrounding the hair follicles that may be covered with gray or brown crusts or scales (perifollicular hyperkeratosis). When viewed under a microscope, the hair shaft resembles a string of evenly-spaced beads. In most cases, monilethrix is thought to be inherited as an autosomal dominant trait. (For more information on this disorder, choose "monilethrix" as your search term in the Rare Disease Database.)
Alopecia areata is a rare disorder characterized by the progressive loss of hair. It often begins suddenly with oval or round bald patches appearing on the scalp; however, other areas of hairy skin may also be involved. Gradually, the affected skin becomes white and smooth. The hair may regrow in these areas within weeks; at the same time, additional patches of hair loss may occur elsewhere. In some cases, hair regrowth may occur in one area of the scalp but not in others; in other cases, the loss of hair may be permanent and lead to baldness. In a few rare cases, all body hair may be lost. Cases with onset during childhood tend to be more severe than those with an adult onset. The exact cause of alopecia areata is unknown. (For more information on this disorder, choose "Alopecia Areata" as your search term in the Rare Disease Database.) .
Diagnosis When an individual exhibits unexplained baldness, a diagnosis of trichotillomania may be suspected. Because many individuals attempt to conceal their hair pulling behavior, a diagnosis may be difficult to obtain. To differentiate trichotillomania from other disorders, surgical removal and microscopic examination of scalp tissue (biopsy) may be used to reveal characteristic results of hair-pulling behavior (e.g., plus of fibrous protein [keratin] and characteristic changes in the structure of the hair follicles [trichomalacia] with no signs of inflammation).
Treatment Psychoanalysis, intensive psychotherapy, and behavior-modification therapy such as habit reversal may be helpful for some individuals with trichotillomania. In some cases, medications, specifically anti-depressants known as serotonin reuptake inhibitors (SRIs), may be used to treat individuals with trichotillomania. Such medications include chlorpromazine isocarboxazid, amitriptyline and imiprimine. In some cases, behavior modification and medications are used together to treat the disorder. .
The drug clomipramine, an antidepressant, has been approved by the Food and Drug Administration (FDA) for treating obsessive compulsive disorders. The drug is being investigated as a treatment for trichotillomania. Clomipramine works by enhancing levels of the chemical serotonin in the brain. (Serotonin transmits messages between nerve cells). The drug is manufactured by Ciba-Geigy.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Ninan PT. Conceptual issues in trichotillomania, a prototypical impulse control disorder. Curr Psychiatry Rep. 2000;2:72-75.
Casati J, et al. Psychosocial issues for women with trichotillomania. Compr Psychiatry. 2000;41:344-51.
Neziroglu F, et al. Behavioral, cognitive, and family therapy for obsessive-compulsive and related disorders. Psychiatr Clin North Am. 2000;23:657-70.
O'Sullivan RL, et al. Characterization of trichotillomania. A phenomenological model with clinical relevance to obsessive-compulsive spectrum disorders. Psychiatr Clin North Am. 2000;23:587-604.
Sharma NL, et al. Trichotillomania and trichophagia leading to trichobezoar. J Dermatol. 2000;27:24-26.
Van Ameringen M, et al. The potential role of haloperidol in the treatment of trichotillomania. J Affect Disord. 1999;56:219-26.
Ko SM, et al. Under-diagnosed psychiatric syndrome. I: Trichotillomania. Ann Acad Med Singapore. 1999;28:279-81.
Schulte-Markwort M, et al. Trichobezoar in a 16-year-old girl. Case report and review of the literature. Nervenarzt. 2000;71:584-87.
Obsessive-Compulsive Foundation, Inc. PO Box 9573 New Haven, CT 06535 Tel: (203)401-2070 Fax: (203)401-2076 Email: info@ocfoundation.org Internet: http://www.ocfoundation.org
Federation of Families for Children's Mental Health 1101 King Street Suite 420 Alexandria, VA 22314 USA Tel: (703)684-7710 Fax: (703)836-1040 Email: ffcmh@ffcmh.org Internet: http://www.ffcmh.org
National Mental Health Consumers' Self-Help Clearinghouse 1211 Chestnut Street Suite 1207 Philadelphia, PA 19107-6312 USA Tel: (215)751-1810 Fax: (215)636-6312 Tel: (800)553-4539 Email: info@mhselfhelp.org Internet: http://www.mhselfhelp.org
National Mental Health Association 2001 North Beauregard Street 12th Floor Alexandria, VA 22311 USA Tel: (703)684-7722 Fax: (703)684-5968 Tel: (800)969-6642 TDD: (800)433-5959 Email: infoctr@nmha.org Internet: http://www.nmha.org
National Alliance for the Mentally Ill Colonial Place Three 2107 Wilson Blvd. Suite 300 Arlington, VA 22201-3042 ISA Tel: 7035247600 Fax: 7035249094 Tel: 8009996264 TDD: 7035167227 Email: membership@nami.org Internet: http://www.nami.org
NIH/National Institute of Mental Health 6001 Executive Blvd Rm 8184, MSC 9663 Rockville, MD 20892-9663 Tel: (301)443-4513 Email: nimhinfo@nih.gov Internet: http://www.nimh.nih.gov/
Trichotillomania Learning Center 303 Potrero St Suite 51 Santa Cruz, CA 95060 USA Tel: (831)457-1004 Fax: (831)426-4383 Email: info@trich.org Internet: http://www.trich.org/home/default.asp
MUMS (Mothers United for Moral Support, Inc) National Parent-to-Parent Network 150 Custer Court Green Bay, WI 54301-1243 USA Tel: (920)336-5333 Fax: (920)339-0995 Tel: (877)336-5333 Email: mums@netnet.net Internet: http://www.netnet.net/mums/
Locks of Love 2925 10th Ave North Suite 102 Lake Worth, FL 33461 Tel: (561)963-1677 Fax: (561)963-9914 Tel: (888)896-1588 TDD: (561)963-1677 Email: info@locksoflove.org Internet: http://www.locksoflove.org
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). CIGNA members can access the complete report by logging into myCIGNA.com. For non-CIGNA members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email orphan@rarediseases.org
Last Updated: 4/25/2008 Copyright 1990, 1995, 2001 National Organization for Rare Disorders, Inc.
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.